课题基金 / 基金详情

Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI

Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI
靶向肾脏嘌呤信号传导治疗锂诱导的 NDI
批准号:
8259070
负责人:
BELLAMKONDA K KISHORE
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-04-01 至 2014-03-31
关键词:
AcuteAdverse effectsAffectAgonistAmilorideAnxietyArgipressinBiologicalBiological ModelsBipolar DisorderBloodCardiovascular systemCell Culture TechniquesCellsChemosensitizationChronicClinicalClinical TrialsCoagulation ProcessCombined Modality TherapyConsciousCulture MediaDataDehydrationDevelopmentDrug Delivery SystemsDuct (organ) structureElderlyElectrolytesEquilibriumEvaluationEventFormulariesFreedomFunctional disorderFundingFutureGeneral PopulationGeneticGoalsHealthcareHypernatremiaHypovolemiaInfusion proceduresInjection of therapeutic agentInterventionIntoxicationInvestigationIraqKidneyKnock-outKnockout MiceKnowledgeLaboratoriesLifeLiquid substanceLithiumMajor Depressive DisorderMarinesMarketingMediatingMental DepressionMethodsMissionModalityModelingMolecularMorbidity - disease rateMusNatureNephrogenic Diabetes InsipidusNucleotidesOutcomeP2Y2 receptorPTGS2 genePathway interactionsPatientsPharmaceutical PreparationsPhysiologicalPlavixPlayPost-Traumatic Stress DisordersPrevalencePurinoceptorRattusReceptor GeneReplacement TherapyReportingResearchResistanceRiskRoleSafetyScreening procedureSignal TransductionSoldierStagingSubstance abuse problemSurveysSystemTechniquesTherapeuticTherapeutic AgentsTherapeutic UsesTissue SampleTissuesUrineV2 ReceptorsVasopressinsVeteransVietnamWarWaterWild Type MouseWorkabstractinganalogbaseclinical practiceclinically relevantclopidogreldesignextracellularfeedinghemodynamicshigh riskimprovedin vivoinfancyinhibitor/antagonistinnovationinsightmeetingsmortalitynovelolder patientoperationpreventpurinoceptor P2Y4receptorresearch studyresponsesocialsuccesssuicidal riskurinary

项目摘要

项目成果

BELLAMKONDA K KISHORE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): 6. Project Summary/Abstract Nephrogenic diabetes insipidus (NDI) due to lithium therapy for bipolar disorder is one of the major nephrological problems among Veterans. NDI is a debilitating condition with an elevated risk of morbidity and even mortality, especially in elderly Veterans. Currently used therapeutic modalities for NDI are encountered with varying degrees of success as well as side effects, including lithium intoxication. Refinement and/or replacement of the current side effect-prone therapies with new drugs based on an improved understanding of molecular pathophysiology of lithium-induced NDI should result in improved efficacy and fewer side effects. Research carried out by us during the current funding period provided significant insights into the potential role of purinergic signaling in the genesis of lithium-induced NDI. These are: (i) purinergic signaling may play a potential overarching role in balancing the effect of arginine vasopressin (AVP) on the urinary concentration mechanism; (ii) in lithium-induced NDI, purinergic signaling in the medullary collecting duct is sensitized and involves more than one subtype of P2Y receptors; and (iii) P2Y2 receptor gene knockout mice are significantly resistant to the development of lithium-induced NDI, suggesting the potential role of purinergic signaling in the genesis of lithium-induced NDI. Based on our novel and significant observations we hypothesize that a deeper understanding of the role of renal purinergic signaling in Li-induced NDI offers better therapeutic modalities. A new class of drugs that target purinergic signaling may improve the safety and/or efficacy of the current medications in combination therapies, or replace them in the treatment of Li-induced NDI. The specific objective of the project are: 1) to investigate the role of purinergic signaling in the development of Li-induced AVP resistance using P2Y2 receptor knockout and wild type mice; 2) to investigate the role of purinergic signaling in Li-induced AVP resistance of medullary collecting duct using primary cultures of mouse inner medullary collecting duct cells; and 3) to investigate the effect of amiloride and COX-2 inhibition on Li-induced NDI in a background of blunted purinergic signaling. To achieve our objectives we will use P2Y2 receptor knockout mice, rats and cell culture models, and employ molecular, functional, immunohistochemical and cell signaling techniques. PUBLIC HEALTH RELEVANCE: 7. Project Narrative Post-traumatic stress disorder, often seen in Veterans, predisposes them to bipolar disorder. Currently there are more than 27 million Veterans, of which about 4% suffer from bipolar disorders. About 30% of bipolar Veterans receive lithium treatment, which is the drug of choice because of low suicidal risk in lithium treated patients. However, the therapeutic use of lithium is associated with a major side effect, called nephrogenic diabetes insipidus (NDI). NDI is associated with morbidity and even mortality, if not treated properly. Currently used medications for the treatment of NDI have side effects and may not be safe all patients. The observations made by us on the potential role of purinergic signaling in lithium-induced NDI at this VA facility opened an avenue for the development of better therapeutic modalities for the treatment of lithium-induced NDI. This grant application proposes studies to further strengthen these concepts.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI
Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI
Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI
Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI
海外基金